Physician profile
Marshall Cooper
NPI 1568539252
$1,952.39
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $318 · 2021: $322 · 2022: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $748.96 | 2019-2022 | |
| Organogenesis INC. | $439.47 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $282.02 | 2019-2020 | |
| Integra Lifesciences Corporation | $167.75 | 2019-2020 | |
| Axogen | $97.17 | 2019 | |
| Smith+Nephew, INC. | $89.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.91 | 2019 | |
| Kerecis Limited | $19.63 | 2019 | |
| Paragon 28, INC. | $17.08 | 2019 | |
| Abbott Laboratories | $15.33 | 2019 | |
| Glaxosmithkline, LLC. | $14.06 | 2019 | |
| Misonix INC | $12.56 | 2019 | |
| Sandoz INC. | $11.67 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.